Overview

Transgene (Euronext: TNG),

part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing targeted immunotherapies for the treatment of cancers and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.

Transgene

Management Committee

Philippe ARCHINARD

Philippe ARCHINARD, PhD
Chairman and Chief Executive Officer

Philippe Archinard became Chief Executive Officer (CEO) in December 2004 and Chairman in June 2010. He has also served as President of Lyonbiopôle, a worldwide competitiveness cluster, since October 2006. Prior to joining Transgene, he served as CEO of Innogenetics, beginning in 2000. He began his professional career with bioMérieux in 1985, where he held various positions in France and the United States, including CEO of U.S. operations. He holds a chemical engineering degree and a PhD in biochemistry from Lyon University and has completed the Program for Management Development (PMD) at Harvard Business School.

Eric QUEMENEUR

Eric QUÉMÉNEUR, PhD
Executive Vice President and Vice President, Research & Development

Eric Quéméneur joined Transgene in September 2014 as Executive Vice President in charge of Research and Development. Before joining Transgene, he spent over 20 years at the CEA (Atomic Energy Commission) where he was Director of research programs and industrial partnerships in the life science division. His responsibilities included: the management of R&D programs and their transition into applications, the management of multidisciplinary teams and the development of national and international alliances. Eric Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France. He is the author of nearly 80 articles published in international scientific journals.


Christophe ANCEL

Christophe ANCEL, PharmD
Vice President, Quality and Qualified Pharmacist

Christophe Ancel joined Transgene in 2008, first as Head of Quality Assurance and then as Vice President, Operational Quality. Prior to that, he was a consultant for several international pharmaceutical groups. From 2001 to 2005, he was Head of Quality, Assistant Pharmacist and Interim Responsible Pharmacist for the French production site of E. Lilly. In 2001, he was Quality Director and Interim Responsible Pharmacist for a Cardinal Health site. From 1992 to 2000, he worked for Alcon Laboratories in quality and was Assistant Pharmacist at the production site. He has international work experience in the areas of production and commercialization of sterile products. He is a Doctor of Pharmacy.

Maud BRANDELY

Maud BRANDELY, MD, PhD
Chief Medical Officer

Maud Brandely joined Transgene as Chief Medical Officer in March 2016. Maud Brandely was previously Director of Clinical Development at Pierre Fabre Oncologie until February 2016. She was responsible for all clinical trials from Phase I to Phase III trials. As such, she was involved in the successful registrations of Navelbine oral in breast cancer and NSCLC and vinflunine in transitional cell carcinoma of the urothelial tract. Prior to Pierre Fabre, Maud Brandely was Director of Taxotere clinical development at Rhone-Poulenc (RPR, now Sanofi) and was responsible for setting up global registration of clinical studies in both the US and Europe. As such she shared her time between Collegeville and Paris to oversee her US and European teams. Before RPR, she worked at Hoescht-Roussel-Uclaf (now Sanofi) and was involved in the development of cytokines (Il2, IFN) and cytotoxics. Maud is an MD and obtained a PhD in Immunology.

Jean-Philippe DEL

Jean-Philippe DEL
Vice President, Finance

Jean-Philippe Del became Vice President, Finance at Transgene in 2014, previously serving as Finance Senior Director. He joined the Company in 2005 and has been responsible for management control, accounting and purchasing. Before joining Transgene, he was a financial auditor with Mazars and began his career in 2001 as a financial controller at Kronenbourg Breweries. Jean-Philippe Del has a post-graduate degree in accounting and finance (DESCF) and a master’s degree from the University of Strasbourg.

Thibaut DU FAYET

Thibaut DU FAYET
Vice President, Alliance Management, Project Management & Marketing

Thibaut du Fayet joined Transgene in 2008 and is in charge of project management, alliance management and marketing at Transgene. From 2007 to 2008, he was responsible for marketing at Stallergenes. Prior to that, he held various positions in corporate strategy and business development at bioMérieux (2003 -2007) and Rhodia/Rhone-Poulenc (1999-2003). Prior to his industry experience, he spent six years working as a Management Consultant at Bossard/Gemini Consulting. Thibaut du Fayet has an MBA from ESSEC Management School and holds an MA in International Finance from Brandeis University (Boston).

John FELITTI

John FELITTI
Vice President, Corporate Secretary & General Counsel

John Felitti joined Transgene in March 2016 as General Counsel & Corporate Secretary. Before joining Transgene, he was Associate Vice President, Corporate Law, Finance & Securities Law at Sanofi and previously held other positions in the Sanofi and the Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices of the global U.S. law firm Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. After majoring in economics at Harvard University (AB 1991) and the College of Europe (MA 1993), John Felitti studied law at the University of Michigan (JD 1996) and the University of Paris II – Panthéon (LLM 1997). He also holds a business degree from INSEAD (GEMBA 2015).

Hemanshu SHAH

Hemanshu SHAH, PhD
Vice President, Corporate Development & Medical Affairs

Hemanshu Shah joined Transgene in May 2014. Mr. Shah has more than 25 years’ experience in the pharmaceutical/biotechnology industries in a variety of functional and therapeutic areas, with significant experience in oncology. Prior to joining Transgene, he was Vice President of Global Marketing and Therapeutic Area Head for Infectious Diseases, Transplantation, Immunology and Dermatology at Astellas (2012-2014). Before Astellas, he was Chief Operating Officer at Arog Pharmaceuticals (2010-2011), Chief Business Officer at Innate Pharma (2008-2010) and Vice President of Commercial Operations at GPC Biotech (2003-2008). Hemanshu Shah was Global Commercial Leader for Oncology at Johnson & Johnson (2002-2003) and held a variety of positions of increasing responsibility at Bristol-Myers Squibb (1988-2002). He has a PhD in Pharmaceutical Sciences from Rutgers University and an MBA from SUNY (Buffalo).

Board of Directors

  • Philippe ARCHINARD, PhD, Chairman & Chief Executive Officer
  • Jean-Luc BÉLINGARD, Director
  • Antoine BÉRET, Independent Director, Chairman of the Compensation Committee
  • Jean-Pierre BIZZARI, MD, Independent Director
  • Benoît HABERT, Independent Director, Chairman of the audit committee
  • Patrick HURTELOUP, MD, Independent Director
  • Jean-François LABBÉ, Independent Director
  • Alain MÉRIEUX, Director
  • TSGH, Director, represented by Dominique TAKIZAWA
  • Laurence ZITVOGEL, MD, Independent Director

Last update : June 2016.

Our History

2016

In 2016, Transgene announced its new strategic development plan, secured new financing and completedits 2015 restructuring program. The new funding consisted of a €20 million loan from the European Investment Bank (EIB) under the IDFF (Infectious Diseases Finance Facility) program plus a €46 rights issue. The Company’s strategy is based on its unique strengths in the immune-engineering of viral vectors and on its expertise in pre-clinical and clinical development. Transgene’s priority is to combine its products with other immunotherapy products, including immune checkpoint inhibitors, a new class of promising therapeutics, for the treatment of cancers and infectious diseases. The Company is also strengthening its translational research capabilities through collaborations with academic institutions and hospitals.

2014

Transgene successfully completed a rights issue and private placement that together raised a total of €65.5 million.

2013

Transgene with Sanofi announced a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapies, including Transgene’s therapeutic products. The platform is being built on the Genzyme Polyclonals site in Lyon.

2012

The Company’s 50:50 joint venture with Tasly Pharmaceuticals Group Co. Ltd. began operations in China. The joint venture was set up with the goal of developing and commercializing Transgene products for the Chinese market. Tasly has strong experience developing, manufacturing and commercializing biologics in China.

2010

In 2010, the Company reinforced its capital structure through a rights issue, raising €152 million. Transgene also entered into an exclusive partnership with Jennerex, Inc. (now SillaJen Inc.) for the development and commercialization in certain territories of Jennerex’s oncolytic virus Pexa-Vec (JX594/TG6006) for the treatment of solid tumors.

2008

In 2008 the Company moved its headquarters and R&D facilities from the center of Strasbourg to the Illkirch site (near Strasbourg) in the same location as its manufacturing site.

2005: New Management & New Strategy

The metamorphosis of Transgene from a research-based laboratory and early development biotechnology company to a more integrated biopharmaceutical company began in earnest in 2005, with the arrival of the current CEO, Philippe Archinard. New strategic objectives were set that reduced the portfolio of products and focused the Company’s work on discovering and developing therapeutic vaccines in two areas – cancer and infectious diseases. Emphasis was placed on demonstrating proof of concept quickly, and validating partnership agreements were sought with the pharmaceutical industry.

21916266_blog

Transgene launched a successful IPO, raising $100 million, on the Nouveau Marché (now Euronext) and Nasdaq in 1998. The Mérieux family, through its family holding company, continued to maintain a majority stake and offer ongoing support to the Company. The subsequent years were marked by continued pre-clinical and clinical development of its products, and in 2001 Transgene decided to focus mainly on unmet medical needs in cancer.

1995: Construction of Bio-production Unit at Illkirch

Transgene opened its own manufacturing unit in 1995 with the objective of controlling the supply of clinical material needed to support the Company’s clinical trial programs.

1994: Support of the Merieux Family

 With the support of a group of private investors led by Alain Mérieux, who took control of the Company in 1994, Transgene developed a family of five vectors for the delivery of genes aimed at treating a wide range of serious diseases, including cystic fibrosis, cancer, muscular dystrophy and cardiovascular disease.

1992: Development of Proprietary Technology

In 1992, with the substantial experience gained in third-party research, Transgene re-positioned itself as a biotechnology company. The increasing recognition of the Company’s groundbreaking scientific research, based on its core competencies in molecular and cellular biology, encouraged Transgene to focus its efforts on developing proprietary gene transfer technologies using viral vectors to treat a variety of life-threatening diseases.

1979: Transgene Founded

Transgene was founded in December 1979 with the scientific support of world-renowned biologists, Prof. Pierre Chambon and Prof. Philippe Kourilsky. In its early years, and under the direction of Dr. Jean-Pierre Lecocq, the Company focused on carrying out third-party research projects in the fields of genetic engineering, immunology, virology, molecular and cellular biology and protein chemistry. The Company’s research on behalf of companies operating in the human and animal healthcare sectors led to a notable success: the commercialization by Rhône Mérieux (Mérial) of a new vaccine designed by Transgene (Raboral®), based on an attenuated live vaccinia virus, to stem the advance of rabies in wild animal populations.

Subsidiaries and Holdings

Subsidiaries

Transgene has a wholly owned subsidiary in the United States, Transgene, Inc., located in Cambridge, Massachusetts. This subsidiary represents Transgene S.A. before various bodies, regulatory authorities and clinical sites for clinical trials that it conducts in the United States.

Holdings

The Company has equity stakes in Transgene Tasly (Tianjin) Biopharmaceutical Co. Ltd. (50%), and ElsaLys Biotech SAS (24.99%).

Transgene Tasly (Tianjin) Biopharmaceutical Co. Ltd. is a Chinese company, founded in 2010 to develop and ultimately sell biotechnology products, including those of Transgene, in China. It is jointly owned with Tasly Pharmaceuticals Group, based in Tianjin, China.

ElsaLys Biotech SAS was founded in 2013 by former Transgene executives to develop monoclonal antibodies.